VTRS News and Press, Viatris Inc. From 08/18/23

2023-08-18 13:09:45 ET Summary On August 7, Viatris released its financial results for the 2nd quarter of 2023, which, after a long time, finally managed to beat analysts' expectations. Viatris' revenue for the second quarter of 2023 was $3.92 billion, up 5.1% from the previous qu...

2023-08-18 07:45:00 ET Viatris (NASDAQ: VTRS) hasn't made for a particularly great investment since it formed nearly three years ago, through a merger of Mylan and Pfizer 's Upjohn business. Down 29% since then, it has been an underwhelming healthcare stock, to say the least. Bu...

2023-08-16 11:06:18 ET Viatris (NASDAQ: VTRS) could be on the verge of eating the lunch of Novo Nordisk 's (NYSE: NVO) two golden cash cows: The diabetes drug Ozempic, and another version that's formulated for weight loss called Wegovy. If everything goes according to plan, ...

2023-08-11 10:00:00 ET Dividend stocks can be great additions to anyone's portfolio, and it's even better to buy quality ones when they're down. While the market has roared back this year following a downturn in 2022, it is still possible to find solid dividend-paying companies lagging the ...

2023-08-11 08:25:00 ET Viatris (NASDAQ: VTRS) spun off from Pfizer and merged with Mylan back in 2020. It's a generic drugmaker with a diverse, global business that serves patients and customers in over 165 countries and territories. It has approximately 40 manufacturing facilit...

2023-08-11 04:04:38 ET Summary Viatris reported strong second-quarter earnings, beating estimates on both revenue and earnings per share. The company showed signs of sales growth on a divestiture adjusted basis and is on track for $500 million of new product revenue. Managemen...

2023-08-10 22:20:45 ET Summary Davis Selected Advisers' 13F portfolio increased by 8% to $16.41B in Q2 2023. The top three holdings in the portfolio are Meta Platforms, Berkshire Hathaway, and Wells Fargo. Stake increases were seen in Wells Fargo, Capital One Financial, Viatri...

2023-08-10 11:01:31 ET Summary Organon & Co. posted its Q2 2023 earnings on 8th August. The Merck spinouts' 3 main divisions are Women's Health, Biosimilars, and Established Brands. Total revenues were $1.6bn - up 4% ex-FX fluctuations - and diluted EPS was $0.95 - both ou...

2023-08-09 09:37:00 ET Viatris (NASDAQ: VTRS) is a stock of immense interest among the dividend investing community, and it's no surprise why. Generic drugmakers, when operating smoothly, can be veritable cash machines for years on end. But as all investors should know, companie...

2023-08-08 10:34:31 ET Summary Viatris Inc. announced its Q2 2023 earnings yesterday. Total net sales were $3.9bn, and free cash flow $447m. While like-for-like product sales grew year-on-year, EBITDA and FCF declined significantly, owing to increased SG&A and R&D spending...